Oncology/Hematology
News, opinions and meeting coverage in oncology/hematology.
— Three cycles could become the new standard for retinoblastoma, researchers say
Latest in Oncology/Hematology
Retrospective study answers questions raised in shift to screening at age 45
Zolbetuximab indicated alongside fluoropyrimidine- and platinum-containing chemotherapy
-- News, features, and commentary about cancer-related issues
In confirmatory trial, antibody-drug conjugate failed to improve OS versus chemotherapy
-- News, features, and commentary about cancer-related issues
In confirmatory trial, antibody-drug conjugate failed to improve OS versus chemotherapy
Oncology/Hematology Case Studies
Rare condition can be deadly without early diagnosis and treatment
Nonspecific presentation impedes early diagnosis of rare indolent tumor in older man
Be aware of the potential for secondary malignancy in relation to LCH diagnosis, researchers urge
More in Oncology/Hematology
Absolute risk remains low, however
Health news and commentary gathered by 51˶ staff
Odds of undetectable PSA at 48 weeks doubled with addition of Pluvicto
May become "treatment of choice" over brentuximab vedotin for all disease stages
Trials now enroll lower-risk women who get better treatment, analysis suggests
Low rates of toxicity and salvage cystectomy, with 2-year survival similar to surgery
First once-weekly subcutaneous prophylactic option for hemophilia B
Debate highlights pros and cons of the new recommendation
Likelihood of severe maternal morbidity more than 20 times higher versus the general population
Health news and commentary gathered by 51˶ staff
Adding inavolisib to palbociclib/fulvestrant more than doubled PFS in endocrine-resistant disease
Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone
News, features, and commentary about cancer-related issues
10% of patients in trials leading to eli-cel's approval developed MDS or AML
